You are here

Product Pipeline

Our Medicines in Development

Our priority is researching and developing products and treatments that will benefit patients around the world. And from specialized efforts in biosimilars and rare disease to oncology and vaccines, we are committed to developing medical solutions that will matter most to the people we serve.

Key Innovative Programs in Registration / Phase 3

  • Bavencio (avelumab): Non-Small Cell Lung Cancer, Gastric Cancer, Ovarian Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Urothelial Cancer (in collaboration w/ Merck KGaA)
  • Ertugliflozin: Type 2 Diabetes (in collaboration w/ Merck)
  • Ibrance (palbociclib): High Risk  Early Breast Cancer, Early Breast Cancer in Adjuvant Setting, HER2+ Breast Cancer
  • lorlatinib (PF-06463922) (ALK/ROS1): Non-Small Cell Lung Cancer
  • Prophylactic Vaccine for Clostridium difficile Infection
  • Rivipansel: Vaso-Occlusive Crisis Associated with Sickle Cell Disease
  • somatrogon (PF-06836922): Adult Growth Hormone Deficiency, Pediatric Growth Hormone Deficiency (in collaboration w/ OPKO)
  • talazoparib (MDV3800): Breast Cancer
  • Tanezumab: OA Signs and Symptoms, Chronic Low Back Pain, Cancer Pain
  • Vyndaqel (tafamidis meglumine): Cardiomyopathy
  • Xeljanz® (tofacitinib): Ulcerative Colitis, Psoriatic Arthritis
  • Xtandi (enzalutamide): Prostate Cancer

Key Biosimilars Programs in Registration / Phase 3

  • A potential biosimilar to Humira® (adalimumab): Rheumatoid Arthritis
  • A potential biosimilar to Avastin® (bevacizumab): Non-Small Cell Lung Cancer
  • A potential biosimilar to Epogen® and Procrit® (epotein alfa): Anemia
  • A potential biosimilar to Remicade® (infliximab): Rheumatoid Arthritis (ex-European Economic Area)
  • A potential biosimilar to Rituxan®/MabThera (rituximab): Follicular Lymphoma
  • A potential biosimilar to Herceptin® (trastuzumab): Breast Cancer

Key Programs in Phase 2

  • Coagulation Factor IX (F9): Hemophilia
  • Dekavil (IL-10 Inhibitor): Rheumatoid Arthritis
  • domagrozumab (PF-06252616) (Myostatin Inhibitor): Duchenne Muscular Dystrophy
  • Dopamine 1 activator: Parkinson’s Disease
  • glasdegib (PF-04449913) (SMO Inhibitor): Acute Myeloid Leukemia
  • Ibrance (palbociclib): Squamous Cell Carcinoma of the Head and Neck
  • IRAK4 Inhibitor: Rheumatoid Arthritis
  • JAK1 Inhibitor: Atopic Dermatitis
  • JAK3 Inhibitor: Alopecia Areata, Rheumatoid Arthritis, Ulcerative Colitis
  • Prophylactic Vaccine for Staphylococcus aureus Infection
  • TYK2/JAK1 Inhibitor: Alopecia Areata, Psoriasis, Ulcerative Colitis
  • Xtandi (enzalutamide): Hepatocellular Carcinoma


Remicade® is a registered U.S. trademark of Janssen Biotech, Inc.; Rituxan® is a registered U.S. trademark of Biogen MA Inc.; MabThera is a trademark of F. Hoffmann La Roche AG; Avastin® and Herceptin® are registered U.S. trademarks of Genentech, Inc.; Humira® is a registered U.S. trademark of Abbvie Biotechnology Ltd.; Epogen® is a registered U.S. trademark of Amgen Inc.; Procrit® is a registered U.S. trademark of Johnson & Johnson